A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT ID: NCT06668961

Last Updated: 2026-01-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-07
• Study Completion Date: 2026-11-30

Brief Summary

This study is a open, multi-center phase II clinical study to explore the efficacy, safety and pharmacokinetic/pharmacodynamic characteristics of SI-B001+SI-B003 combined with platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Conditions

Head and Neck Squamous Cell Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort A

Participants will receive treatment during the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

SI-B001

Intervention Type: DRUG

Administration by intravenous infusion

SI-B003

Intervention Type: DRUG

Administration by intravenous infusion

Cohort B

Participants will receive treatment during the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

SI-B001

Intervention Type: DRUG

Administration by intravenous infusion

Interventions

SI-B001

Administration by intravenous infusion

Intervention Type: DRUG

SI-B003

Administration by intravenous infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Sign the informed consent form voluntarily and follow the protocol requirements;

2. Gender is not limited;

3. Age ≥18 years old and ≤75 years old;

4. Expected survival time ≥3 months;

5. Patients with recurrent or metastatic head and neck squamous cell carcinoma;

6. Consent to provide tumor tissue samples or fresh tissue samples archived from the primary or metastatic lesions within 2 years;

7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

8. Physical status score: ECOG ≤1;

9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

11. No blood transfusion or colony-stimulating factor was allowed within 14 days before the first use of the study drug, and the organ function level must meet the requirements;

12. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5×ULN;

13. Urinary protein ≤1+ or ≤1000mg/24h;

14. Fertile female subjects, or male subjects with fertile partners, must use highly effective contraception from 7 days before the first dose until 24 weeks after the dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.

Exclusion Criteria

1. Squamous cell carcinoma of the nasopharynx, salivary gland, paranasal sinus, skin or of unknown primary site;

2. Patients with any of the following conditions were not eligible for the study: a) suitable and willing for local treatment; b) received systemic therapy, excluding treatment for locally advanced disease as part of multimodal therapy;

3. Patients with active central nervous system metastasis;

4. Who had participated in any other clinical trial within 4 weeks before the study dose;

5. Received radiotherapy within 4 weeks before the first dose of study drug;

6. Use of traditional Chinese medicine with anti-tumor indications within 2 weeks;

7. Had undergone major surgery within 4 weeks before the first dose;

8. Systemic corticosteroids or immunosuppressive agents were required within 2 weeks before study dosing;

9. Pulmonary disease was defined as ≥ grade 3 according to NCI-CTCAE v5.0; Patients with existing or a history of interstitial lung disease (ILD);

10. Have active infection requiring intravenous anti-infective therapy;

11. Had received immunotherapy and had grade ≥3 irAE or grade ≥2 immune-related myocarditis;

12. Received live attenuated vaccine within 4 weeks before the first dose of study drug;

13. Had taken an immunomodulatory drug within 14 days before the first dose of study drug;

14. Patients at risk for active autoimmune disease or with a history of autoimmune disease;

15. Other malignant tumors within 5 years before the first administration;

16. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;

17. Poorly controlled hypertension;

18. Patients with poor blood glucose control before the first dose;

19. Had a history of severe cardiovascular and cerebrovascular diseases;

20. Previous history of allogeneic stem cell, bone marrow or organ transplantation;

21. Patients with massive or symptomatic effusions or poorly controlled effusions;

22. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of SI-B001 or SI-B003;

23. Had severe infusion reactions to antibody therapy in the past;

24. Had autologous or allogeneic stem cell transplantation;

25. Pregnant or lactating women;

26. The investigator did not consider it appropriate to apply other criteria for participation in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Dongmei Ji

Role: primary

Other Identifiers

SI-B001-SI-B003-203

Identifier Type: -

Identifier Source: org_study_id